MetALD Cases More Than Double Since 1990 as 1 in 10 U.S. Adults Face Overlapping Risks
Updated
Updated · STAT · May 13
MetALD Cases More Than Double Since 1990 as 1 in 10 U.S. Adults Face Overlapping Risks
2 articles · Updated · STAT · May 13
MetALD is emerging as a major U.S. liver-disease threat as doctors report more serious illness and deaths among younger people and women.
The condition develops when liver fat and metabolic risks such as obesity, diabetes, high blood pressure or high cholesterol combine with alcohol intake above 10 drinks a week for women or 15 for men.
Some studies suggest the share of Americans meeting those criteria has more than doubled since 1990, and a recent JAMA Internal Medicine study found nearly 1 in 10 adults report both heavy drinking and obesity.
The warning builds on a broader fatty-liver burden in the U.S., where related MASLD/MASH disease already affects about 33% of adults.
Fatty liver disease is now a childhood epidemic. What does this reveal about our modern food and environment?
The market for MASH drugs is set to boom. Which new therapy will dominate treatment for this silent killer?
With new drugs now approved for fatty liver, is the obesity crisis finally getting a pharmacological solution?